第三条 公司、公司控股子公司及下属分公司与主要股东及其他关联方发生的 经营性资金往来，包括正常的关联交易产生的资金往来，应当严格按照《股票上市 规则》和公司《关联交易管理制度》进行决策和实施。 第一条 为了建立防止主要股东及关联方占用苏州赛分科技股份有限公司（以 下简称"公司"）资金的长效机制，杜绝主要股东及关联方资金占用行为的发生，根 据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》 （以下简称"《证券法》"）《上海证券交易所科创板股票上市规则》（以下简称"《股 票上市规则》"）《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 等相关规定及《苏州赛分科技股份有限公司章程》（以下简称"《公司章程》"），制 定本制度。 第二条 公司董事、高级管理人员有维护公司资金安全的义务。 苏州赛分科技股份有限公司 防范主要股东及关联方占用公司资金专项制度 第一章 总 则 第六条 公司按照《股票上市规则》、《公司章程》及《关联交易管理制度》等 第四条 本制度所称资金占用包括但不限于以下方式： （一）经营性资金占用：指主要股东及关联方通过采购、销售、相互提供劳务 等生产经营环节的关联交易 ...

苏州赛分科技股份有限公司 对外担保管理制度 （三）公司所属全资公司、持股超过50%的子公司； 第二条 公司对外担保应当遵循合法、审慎、互利、安全的原则，全体董事 及高级管理人员应审慎对待和严格控制对外担保产生的债务风险，并对违规或失 当的对外担保产生的损失依法承担连带责任。控股股东及其他关联方不得强制公 司为他人提供担保。 第三条 本制度适用于公司（包括公司的全资、控股子公司）为他人提供下 列担保的行为：被担保企业因向金融机构贷款、票据贴现、融资租赁等原因向公 司申请为其提供担保，其中包括公司对控股子公司的担保。 第四条 公司对外提供担保，应根据《股票上市规则》及中国证监会的有关 规定披露有关信息。 第二章 对外担保对象 第五条 公司可以为具有独立资格且具有下列条件之一的单位担保： （一）因公司业务需要的互保单位； （二）与公司有现实或潜在重要业务关系的单位； 第一章 总则 第一条 为规范苏州赛分科技股份有限公司（以下简称"公司"）对外担保行 为，控制和降低担保风险，保证公司资产安全，根据《中华人民共和国民法典》 （以下简称"《民法典》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司治理 ...

苏州赛分科技股份有限公司 信息披露管理制度 第一章 总则 第一条 为规范苏州赛分科技股份有限公司（以下简称"公司"）及其他相 关义务人的信息披露行为，加强公司信息披露事务管理，促进公司依法规范运作， 维护公司股东的合法权益，根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司信息披露管理办法》（以下简称"《管理办法》"）、《上海证券交易所科创 板股票上市规则》（以下简称"《股票上市规则》"）、《上市公司治理准则》 以及《苏州赛分科技股份有限公司章程》（以下简称"《公司章程》"）等有关 规定，制定本制度。 第二条 本制度所指"信息"是指所有可能对公司股票价格产生重大影响的 信息以及证券监管部门要求或公司主动披露的信息。信息披露文件的形式主要包 括：招股说明书、募集说明书、上市公告书、定期报告和临时报告等。 第三条 本制度适用于如下机构和人员： （一）公司董事会； （二）公司董事、董事会秘书和公司其他高级管理人员； （三）公司各部门、各控股子公司（包括直接控股和间接控股）、各参股公 司及其主要负责人； （四）公司持股 5%以上的股东； （五）其 ...

第一条 为了进一步完善公司法人治理结构，保证苏州赛分科技股份有限公司 （以下简称"公司"）所有股东充分行使权利，根据中国证监会《上市公司治理准 则》、《上海证券交易所科创板股票上市规则》、《苏州赛分科技股份有限公司章 程》（以下简称"《公司章程》"）及其他有关规定，制定本实施细则。 第二条 本实施细则所指的累积投票制，是指股东会在选举两名以上（含两名） 董事时采用的一种投票方式。即公司选举董事时，每位股东所持有的每一股份都拥 有与应选董事总人数相等的投票权，股东既可以用所有的投票权集中选举一人，也 可以分散选举数人，最后按得票多少依次决定董事人选。 第三条 本实施细则所称"董事"包括独立董事和非独立董事。 第四条 股东会选举产生的董事人数及结构应符合公司章程的规定。 苏州赛分科技股份有限公司 累积投票制实施细则 第五条 股东会对董事候选人进行表决前，会议主持人应明确告知与会股东对候 选董事实行累积投票方式，股东会工作人员应该置备适合实行累积投票方式的选票。 董事会秘书应对累积投票方式、选票填写方法做出说明和解释。 第六条 运用累积投票制选举公司董事的具体表决办法如下： （一）累积投票制的票数计算法 1. 每位 ...

第一条 为规范苏州赛分科技股份有限公司（以下简称"公司"）股东会的表 决机制，保护投资者合法权益，根据《中华人民共和国公司法》（以下简称" 《公司法》"）、《上市公司股东会规则（2025年修订）》、《上海证券交易 所科创板股票上市规则》、《上海证券交易所科创板上市公司自律监管指引第 1号——规范运作》等相关法律、行政法规、规章、规范性文件和《苏州赛分 科技股份有限公司章程》（以下简称"《公司章程》"）的规定，特制订本细则。 第二条 本细则所称公司股东会网络投票系统（以下简称"网络投票系统"） 是指上海证券交易所（以下简称"上交所"）利用网络与通信技术，为公司股东 非现场行使股东会表决权提供服务的信息技术系统。上交所网络投票系统包括 下列投票平台： （一）交易系统投票平台； （二）互联网投票平台（网址：vote.sseinfo.com）。 第三条 公司召开股东会，应当按照相关规定向股东提供网络投票方式，履 行股东会相关的通知和公告义务，做好股东会网络投票的相关组织和准备工作。 第四条 公司为股东提供网络投票方式的，应当按照上交所相关临时公告格 式指引的要求，使用上交所公告编制软件编制股东会相关公告，并按规定披露 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥83,587,089.19, representing an increase of 8.87% compared to ¥76,776,735.66 in the same period last year[3]. - The net profit attributable to shareholders decreased by 1.02% to ¥23,712,621.06 from ¥23,957,060.85 year-on-year[3]. - The net profit for Q1 2025 is CNY 23,880,736.67, a decrease of 2.55% compared to CNY 24,507,260.57 in Q1 2024[15]. - The company reported a comprehensive income total of CNY 23,828,821.34 for Q1 2025, compared to CNY 24,697,375.86 in Q1 2024, indicating a decrease of about 3.5%[17]. - Basic earnings per share for Q1 2025 is CNY 0.0593, down from CNY 0.0654 in Q1 2024, representing a decline of approximately 9.3%[17]. Cash Flow and Liquidity - The net cash flow from operating activities dropped significantly by 97.56% to ¥396,039.16, down from ¥16,229,892.37 in the previous year[3]. - The cash flow from operating activities shows a net increase of CNY 396,039.16, significantly lower than CNY 16,229,892.37 in the same period last year[18]. - The company generated CNY 21,547,815.06 in net cash flow from investing activities in Q1 2025, a significant improvement compared to a negative cash flow of CNY 23,686,987.66 in Q1 2024[19]. - The financing activities generated a net cash flow of CNY 175,038,543.72 in Q1 2025, compared to a negative cash flow of CNY 2,044,558.45 in Q1 2024, indicating a strong improvement in financing[19]. - Cash and cash equivalents increased to ¥299,817,279.15 from ¥103,080,898.09, representing a growth of 189.5%[10]. Assets and Liabilities - The total assets at the end of the reporting period increased by 14.94% to ¥1,358,984,272.87 from ¥1,182,310,293.37 at the end of the previous year[3]. - Current assets as of March 31, 2025, totaled ¥785,539,359.11, a significant increase of 33.0% from ¥590,390,238.19 at the end of 2024[10]. - Total assets reached ¥1,358,984,272.87, an increase of 15.0% from ¥1,182,310,293.37 at the end of 2024[12]. - Total liabilities decreased to ¥70,716,025.89 from ¥84,269,862.24, a reduction of 16.1%[12]. - Shareholders' equity increased to ¥1,288,268,246.98, up 17.3% from ¥1,098,040,431.13 at the end of 2024[12]. Operating Costs and Expenses - Total operating costs for Q1 2025 were ¥53,628,737.30, up 14.7% from ¥46,742,557.97 in Q1 2024[14]. - Operating costs included ¥21,613,466.86 in operating expenses, which rose 20.5% from ¥18,010,478.67 in Q1 2024[14]. - The total tax expenses for Q1 2025 are CNY 3,984,561.36, an increase from CNY 3,010,143.26 in Q1 2024, representing a rise of approximately 32.3%[15]. Research and Development - Research and development expenses totaled ¥11,284,285.02, which is an increase of 10.23% compared to ¥10,237,437.10 in the same period last year[3]. - R&D expenses accounted for 13.50% of operating revenue, up from 13.33% year-on-year, indicating a slight increase in investment in innovation[3]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,961, indicating a stable shareholder base[7]. - The weighted average return on equity decreased by 0.41 percentage points to 1.96% from 2.37% in the previous year[3].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 25% year-over-year growth[18]. - The company achieved operating revenue of CNY 315.46 million in 2024, representing a year-on-year growth of 28.65%[26]. - Net profit attributable to shareholders reached CNY 85.16 million, a 62.25% increase compared to the previous year[27]. - Basic earnings per share increased by 62.29% to CNY 0.2324, while diluted earnings per share also rose by the same percentage[25]. - The company reported a net cash inflow from operating activities of CNY 66.01 million, up 52.22% year-on-year[27]. - The company's total assets at the end of 2024 were CNY 1.18 billion, reflecting a 7.29% increase from the previous year[26]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization strategies[18]. - The net profit attributable to the parent company was 85.16 million yuan, a year-on-year increase of 62.25%, with a net profit margin significantly improved due to operational leverage[37]. Research and Development - The company is investing in R&D, allocating 10% of its revenue towards developing advanced separation technologies[16]. - Research and development expenses accounted for 13.59% of operating revenue, a decrease of 4.44 percentage points from the previous year[25]. - The R&D team has over 20 years of experience, developing advanced techniques in key areas such as microsphere synthesis and functional biomolecule synthesis, which are crucial for maintaining a competitive edge against international rivals[82]. - The company has introduced 34 new patent applications in 2024, including 28 invention patents, and has a total of 75 effective authorized patents, of which 24 are invention patents[52]. - The company has developed unique core technologies in chromatography medium preparation, which are critical for maintaining its competitive edge in the market[182]. Market Expansion and Strategy - Market expansion plans include entering the Southeast Asian market, targeting a 10% market share within the next two years[18]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in biopharmaceuticals[18]. - The company has established partnerships with three major pharmaceutical firms to co-develop new therapeutic solutions[18]. - The company is actively promoting the replacement of imported materials with domestic alternatives[200]. - The company has established strategic partnerships with leading pharmaceutical companies such as Roche, Eli Lilly, and Pfizer, enhancing its innovation capabilities in drug discovery and scientific research[178]. Production and Operational Efficiency - The company maintained a 100% production plan achievement rate and order delivery rate at its Yangzhou factory during the reporting period[43]. - The Yangzhou production base commenced operations in 2021, with an annual capacity of 24,760 liters and a single batch capacity of 500 liters, making it one of the few companies in the domestic chromatography medium industry with large-scale production capabilities[63]. - The company plans to expand its production capacity to a total of 224,760 liters per year after the completion of the second phase of the Yangzhou project, further enhancing its production capabilities[179]. - The company has a large-scale production base in Yangzhou covering 41,405 square meters, with a biopharmaceutical chromatography medium capacity of 24,760 liters, ensuring stable supply for downstream drug production[179]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period[3]. - The company has disclosed potential risks in the management discussion and analysis section of the report[3]. - The company is facing risks related to potential talent loss in its high-level technical team, which is essential for ongoing innovation and development[184]. - The company faces a potential asset impairment loss of up to 8.71 million yuan and 12.15 million yuan in 2025 and 2026, respectively, if it fails to secure additional orders[190]. - The company is exposed to risks from policy changes in the pharmaceutical industry, which could slow down demand for its chromatography products[193]. Product Development and Innovation - New product launches included a novel chromatography medium that is expected to enhance purification efficiency by 15%[16]. - The company has developed a new seed swelling polymerization technology that simplifies the production process, increases efficiency, and reduces solvent and additive usage, leading to lower production costs compared to traditional methods[141]. - The company has created a core-shell chromatography medium that combines multiple separation mechanisms, breaking the long-standing market monopoly[174]. - The company has developed multiple downstream purification platform technologies across various segments, including antibodies and recombinant proteins, enabling faster adaptation for new project processes[157]. - The company has developed a unique rSPA protein sequence for affinity chromatography media, enhancing alkaline resistance and dynamic capacity[175]. Customer and Market Engagement - The company employs a direct sales model complemented by distribution for domestic sales, utilizing industry exhibitions, customer visits, and internet marketing to secure orders and maintain long-term partnerships with major pharmaceutical companies[64]. - The company has established a comprehensive sales management system, including strict regulations on contract signing, settlement methods, credit policies, and return policies[67]. - The company’s overseas business revenue accounted for 23.02% of total revenue, highlighting its global market presence[185]. - The accounts receivable balance at the end of the reporting period was 96.90 million yuan, representing 30.72% of total revenue, with a collection rate of 57.13% as of March 31, 2025[189]. Industry Trends and Market Outlook - The chromatography medium market in China is projected to reach 13.6 billion CNY in 2024, with an expected growth to 20.3 billion CNY by 2026, reflecting a compound annual growth rate (CAGR) of 22.17% from 2024 to 2026[101]. - The global chromatography medium market is expected to reach 7.5 billion USD in 2024 and grow to 9 billion USD by 2026, with a CAGR of 9.54%[102]. - The demand for chromatography products is increasing due to the rising clinical needs and the rapid development of innovative biopharmaceuticals[118]. - The domestic biopharmaceutical industry is enhancing its R&D capabilities, leading to higher demands for purification processes and creating new business opportunities for chromatography media[134]. - The global biopharmaceutical market grew from $220.2 billion in 2016 to $297.9 billion in 2020, with a CAGR of 7.85%[112].

证券代码：688758 证券简称：赛分科技 公告编号：2025-015 苏州赛分科技股份有限公司 关于取消公司监事会及修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州赛分科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召 开第二届董事会 2025 年第三次会议和第二届监事会 2025 年第二次会议，审议 通过《关于取消公司监事会及修订<公司章程>的议案》,本议案尚需提交公司 2024 年年度股东大会审议。现将相关情况公告如下： 一、关于取消公司监事会的情况 根据《中华人民共和国公司法（2023 年修订）》《上市公司章程指引（2025 年修订）》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等法律法规和规范性文件的最新规定，结合公司实际情况，现取消公司监事会， 监事会的职权由董事会审计委员会行使，《监事会议事规则》等监事会相关制度 相应废止。 二、关于修改《公司章程》的情况 鉴于上述情况，结合相关法律法规的要求，公司拟对《苏州赛分科技股份 有限公司章程》 ...

证券代码：688758 证券简称：赛分科技 公告编号：2025-017 苏州赛分科技股份有限公司 关于使用募集资金置换已支付发行费用的自筹资金 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州赛分科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开 第二届董事会 2025 年第三次会议和第二届监事会 2025 年第二次会议，审议通过 了《关于使用募集资金置换已支付发行费用的自筹资金的议案》，同意使用募集 资金人民币 24,622,264.15 元置换已支付发行费用的自筹资金。前述事项符合募 集资金到账后六个月内进行置换的规定。公司监事会发表了明确同意的意见，中 信证券股份有限公司（以下简称"保荐人"）对本事项出具了明确的核查意见。 现将相关事项公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会核发的《关于同意苏州赛分科技股份有限公司 首次公开发行股票注册的批复》（证监许可〔2024〕1204 号），并经上海证券 交易所同意，公司首次公开发行人民币普通股（A 股）4,997.569 ...

证券代码：688758 证券简称：赛分科技 公告编号：2025-018 苏州赛分科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：容诚会计师事务所（特殊普通合伙） 苏州赛分科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召 开第二届董事会 2025 年第三次会议，审议通过《关于公司续聘 2025 年度财务 和内部控制审计机构的议案》，拟续聘容诚会计师事务所（特殊普通合伙）（以 下简称"容诚"）为本公司 2025 年度的财务与内部控制审计机构，本议案尚需 提交股东大会审议。现将具体情况公告如下： 一、拟聘任会计师事务所的基本情况 截至 2024 年 12 月 31 日，容诚会计师事务所共有合伙人 212 人，共有注册 会计师 1552 人，其中 781 人签署过证券服务业务审计报告。 3.业务规模 容诚会计师事务所经审计的 2023 年度收入总额为 287,224.60 万元，其中 审计业务收入 274,873.42 ...